Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
XPORT-EC-042
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
3 other identifiers
interventional
276
17 countries
217
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Apr 2023
Longer than P75 for phase_3
217 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 3, 2022
CompletedFirst Posted
Study publicly available on registry
November 10, 2022
CompletedStudy Start
First participant enrolled
April 18, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2028
April 23, 2026
April 1, 2026
3.3 years
November 3, 2022
April 22, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Investigator assessed Progression Free Survival (PFS) per RECIST v1.1
From randomization until disease progression (PD) or death, whichever occurs first (up to 34 months)
Secondary Outcomes (7)
Overall Survival (OS)
Up to 34 months
Safety and tolerability of study drug (selinexor and placebo)
From start of study drug administration up to 34 months
Time to First Subsequent Therapy (TFST)
From randomization until date of initiation of first therapy after discontinuation of study drug or death, whichever occurs first (up to 34 months)
Time to Second Subsequent Therapy (TSST)
From randomization until date of initiation of second therapy after discontinuation of study drug or death, whichever occurs first (up to 34 months)
Progression-free survival after initiating a next-line treatment (PFS2)
From randomization until the next-line progression event or death due to any cause, up to 34 months
- +2 more secondary outcomes
Study Arms (2)
Selinexor
EXPERIMENTALParticipants will receive a fixed dose of selinexor 60 milligrams (mg) oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.
Placebo
PLACEBO COMPARATORParticipants will receive matching placebo for selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.
Interventions
Dose: 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
Dose:60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
Eligibility Criteria
You may qualify if:
- Adults (Aged ≥ 18 years)
- Histologically confirmed endometrial cancer (endometrioid, serous, undifferentiated, or carcinosarcoma sub-types) that is TP53 wild type by central NGSHistologically confirmed EC including endometrioid, serous, undifferentiated, and carcinosarcoma
- Must have completed at least 12 weeks of platinum-based chemotherapy (with or without immune checkpoint inhibitors), with a confirmed partial or complete response according to RECIST v1.1
- Must be able to initiate C1D1 within 3-8 weeks after last platinum dose
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate bone marrow function and organ function
You may not qualify if:
- Uterine sarcomas, clear cell or small cell carcinoma with neuroendocrine differentiation
- Palliative radiotherapy administered within 14 days of intended C1D1
- Any gastrointestinal dysfunction that could interfere with the absorption of oral study therapy
- Serious psychiatric or medical conditions that could interfere with study participation or would make study involvement unreasonably hazardous
- Previous treatment with an XPO1 inhibitor
- Stable disease or disease progression after platinum-based chemotherapy
- Pregnancy, breastfeeding, or other legal/ethical restrictions to trial participation
- Known dMMR/MSI-H EC tumors that are medically eligible to receive an immune checkpoint inhibitor
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Karyopharm Therapeutics Inclead
- GOG Foundationcollaborator
- European Network of Gynaecological Oncological Trial Groups (ENGOT)collaborator
- Belgian Gynaecological Oncology Groupcollaborator
- North Eastern German Society of Gynaecological Oncologycollaborator
- The Central and Eastern European Gynecologic Oncology Groupcollaborator
- Israeli Society of Gynecologic Oncologycollaborator
- Australia New Zealand Gynaecological Oncology Groupcollaborator
- Multicenter Italian Trials in Ovarian Cancer (MITO)collaborator
- Grupo Español de Investigación en Cáncer de Ovariocollaborator
- Hellenic Cooperative Oncology Group (HeCOG)collaborator
- Cancer Trials Ireland (CTI)collaborator
- Mario Negri Gynecologic Oncology group (MaNGO)collaborator
Study Sites (217)
The University of Alabama at Birmingham
Birmingham, Alabama, 35205, United States
Honor Health
Phoenix, Arizona, 85016, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
UC DAVIS
Davis, California, 95616, United States
City of Hope National Medical Center
Duarte, California, 91010, United States
Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, 92612, United States
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
Cancer and Blood Specialty Clinic
Los Alamitos, California, 90720, United States
UCLA - Women's Health Clinical Research Unit
Los Angeles, California, 90095, United States
Long Beach Memorial Medical Center
Los Angeles, California, 90806, United States
UC Irvine
Orange, California, 92868, United States
Stanford University
Palo Alto, California, 94304, United States
California Pacific Medical Center
San Francisco, California, 94109, United States
Highlands Ranch Hospital
Highlands Ranch, Colorado, 80129, United States
University of Colorado Cancer Center
Highlands Ranch, Colorado, 80129, United States
Broward Health Medical Center
Fort Lauderdale, Florida, 33316, United States
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
Advent Health
Orlando, Florida, 32804, United States
Grady Hospital
Atlanta, Georgia, 30303, United States
Emory University
Atlanta, Georgia, 30322, United States
Georgia Cancer Center at Augusta University
Augusta, Georgia, 30912, United States
Northeast Georgia Medical Center
Gainesville, Georgia, 30501, United States
Illinois Cancer Specialists
Arlington Heights, Illinois, 60005, United States
NorthShore University Health System
Evanston, Illinois, 60201, United States
Northwest Cancer Center
Dyer, Indiana, 46311, United States
Goshen Health
Goshen, Indiana, 46526, United States
St Vincent Hospital
Indianapolis, Indiana, 46260, United States
Memorial Hospital of South Bend
South Bend, Indiana, 46601, United States
University of Iowa
Iowa City, Iowa, 52242, United States
Our Lady of the Lake Hospital, Inc.
Baton Rouge, Louisiana, 70808, United States
LSU Health Sciences Center New Orleans
New Orleans, Louisiana, 70119, United States
Trials365, LLC
Shreveport, Louisiana, 71133, United States
Tufts Medical Center
Boston, Massachusetts, 02111, United States
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
USON - Minnesota Oncology Hematology
Minneapolis, Minnesota, 55404, United States
University of Minnesota
Minneapolis, Minnesota, 55455, United States
St. Dominic's Gynecologic Oncology
Jackson, Mississippi, 39216, United States
Midwest Ventures Group HCA MId America Division
Kansas City, Missouri, 64132, United States
Washington University School of Medicine
St Louis, Missouri, 63108, United States
Intermountain Health St. Vincent Regional Hospital
Billings, Montana, 59101, United States
Women's Cancer Center of Nevada
Las Vegas, Nevada, 89106, United States
Center Of Hope
Reno, Nevada, 89511, United States
Hackensack Meridian Health Jersey Shore University Medical Center
Neptune City, New Jersey, 07753, United States
Women's Cancer Care Associates, LLC
Albany, New York, 12208, United States
NYU Langone Hospital-Long Island
Mineola, New York, 11501, United States
Northwell Health - Zuckerberg Cancer Center
New Hyde Park, New York, 11042, United States
Mount Sinai Chelsea
New York, New York, 10011, United States
Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
Mount Sinai
New York, New York, 10029, United States
Lenox Hill Hospital
New York, New York, 10075, United States
Northwell Health - Queens Cancer Center
Rego Park, New York, 11374, United States
University of Rochester
Rochester, New York, 14642, United States
Atrium Health Levine Cancer Institute
Charlotte, North Carolina, 28209, United States
Duke Cancer Center
Durham, North Carolina, 27710, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
MetroHealth
Cleveland, Ohio, 44109, United States
Zangmeister Cancer Center
Columbus, Ohio, 43219, United States
ProMedica Flower Hospital
Sylvania, Ohio, 43560, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
Oklahoma Cancer Specialists and Research Institute, LLC
Tulsa, Oklahoma, 74146, United States
Oncology Associates of Oregon
Eugene, Oregon, 97401, United States
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Alliance Cancer Specialists
Langhorne, Pennsylvania, 19047, United States
Magee - Women's Hospital
Pittsburgh, Pennsylvania, 15213, United States
Allegheny Health Network - West Penn Hospital
Pittsburgh, Pennsylvania, 15224, United States
Avera
Sioux Falls, South Dakota, 57105, United States
Chattanooga's Program in Women's Oncology
Chattanooga, Tennessee, 37403, United States
The West Clinic, PLLC dba West Cancer Center
Germantown, Tennessee, 38138, United States
University of Tennessee Medical Center
Knoxville, Tennessee, 37920, United States
University of Tennessee Health Science Center
Memphis, Tennessee, 38103, United States
USON - Texas Oncology, Austin Central
Austin, Texas, 78731, United States
Parkland Health & Hospital System
Dallas, Texas, 75235, United States
Texas Oncology - Dallas
Dallas, Texas, 75246, United States
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Texas Oncology - Fort Worth
Fort Worth, Texas, 76104, United States
Houston Methodist
Houston, Texas, 77030, United States
Texas Oncology - San Antonio
San Antonio, Texas, 78240, United States
Texas Oncology - The Woodlands
The Woodlands, Texas, 77380, United States
Texas Oncology, PC, Tyler
Tyler, Texas, 75702, United States
University of Utah
Salt Lake City, Utah, 84112, United States
University of Virginia
Charlottesville, Virginia, 22908, United States
Swedish Cancer Institute
Seattle, Washington, 98104, United States
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792, United States
Medical College of Wisconsin/ Freodtert Hospital
Milwaukee, Wisconsin, 53226, United States
Border Medical Oncology & Haematology
Albury, New South Wales, 2640, Australia
Macarthur Cancer Therapy Centre
Campbelltown, New South Wales, 2560, Australia
Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050, Australia
Central Coast LHD - Gosford & Wyong Hospitals
Gosford, New South Wales, 2250, Australia
Newcastle Private Hospital
New Lambton Heights, New South Wales, 2305, Australia
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Westmead Hospital
Wentworthville, New South Wales, 2145, Australia
ICON Cancer Centre Southport
Southport, Queensland, 4215, Australia
Toowoomba Hospital
Toowoomba, Queensland, 4350, Australia
Royal Hobart Hospital
Hobart, Tasmania, 7000, Australia
Box Hill Hospital - Eastern Health (Oncology)
Box Hill, Victoria, 3128, Australia
Monash Health
Clayton, Victoria, 3168, Australia
Frankston Hospital
Frankston, Victoria, 3199, Australia
Cabrini Health
Malvern, Victoria, 3144, Australia
Peter MacCallum Cancer Centre/RWH/RMH
Melbourne, Victoria, 3000, Australia
The Royal Adelaide Hospital
Southport, 5000, Australia
Cliniques Universitaires St. Luc
Brussels, 1200, Belgium
AZ Sint Lucas
Ghent, 9000, Belgium
UZ Leuven
Leuven, 3000, Belgium
CHU Ambroise Pare
Mons, 7000, Belgium
CHU UCL Namur, Site Sainte-Elisabeth
Namur, 5000, Belgium
Tom Baker Cancer Centre
Calgary, Alberta, T3H2G5, Canada
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
Nova Scotia Health / QEII Health Sciences Centre / Atlantic Clinical Cancer Research Unit
Halifax, Nova Scotia, B3H 2Y9, Canada
Princess Margaret
Toronto, Ontario, M5G 2M9, Canada
Sunnybrook Research Institute
Toronto, Ontario, M9L 2H9, Canada
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, H2X 0C1, Canada
McGill University Health Centre (MUHC)
Montreal, Quebec, H4A3J1, Canada
Hospital Maisonneuve-Rosemont
Montreal, Quebec, Canada
University Hospital Brno
Brno, 60200, Czechia
University Hospital Ostrava
Ostrava, 70852, Czechia
UH Královské Vinohrady
Prague, 10034, Czechia
General University Hospital in Prague
Prague, 12851, Czechia
Hospital Na Bulovce
Prague, 18100, Czechia
High Technology Hospital Medcenter
Batumi, 6000, Georgia
Todua Clinic
Tbilisi, 0112, Georgia
LTD New Hospitals
Tbilisi, 0114, Georgia
Tbilisi Cancer Center
Tbilisi, 0156, Georgia
JSC - K.Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, 0159, Georgia
Caucasus Medical Centre
Tbilisi, 0186, Georgia
LTD Innova Medical Center
Tbilisi, 0186, Georgia
Multiprofile Clinic "Consilium Medulla"
Tbilisi, 0186, Georgia
Charite Berlin Universitatsmedizin
Berlin, 13353, Germany
Universitätsklinikum Hamburg Eppendorf
Hamburg, 20246, Germany
University Hospital Dresden
Kiel, 01307, Germany
Universitatsklinikum Schleswig-Holstein
Kiel, 24105, Germany
Helios Klinikum Krefeld
Krefeld, 47805, Germany
Universitätsklinik Leipzig
Leipzig, 04103, Germany
Universitätsfrauenklinik Mainz
Mainz, 55131, Germany
Universitätsmedizin Mannheim
Mannheim, 68167, Germany
Klinik und Poliklinik fur Frauenheilkunde und Geburtshilfe GroBhadern
Munich, 80337, Germany
Klinikum Südstadt Rostock
Rostock, 18059, Germany
Universitätsfrauenklinik Ulm
Ulm, 89075, Germany
IASO Hospital
Marousi, Athens, 151 23, Greece
Alexandra Hospital
Athens, 11528, Greece
Hygeia Hospital
Athens, 15123, Greece
Euromedica General Clinic
Thessaloniki, 54645, Greece
Unit of Gynecol.Oncol., Dept.Obstet.Gynecol., Clinical Center, University of Debrecen
Debrecen, 4032, Hungary
Petz Aladár University Teaching Hospital
Győr, 9024, Hungary
St. Vincent's University Hospital
Dublin, Elm Park, D04 T6F4, Ireland
Cork University Hospital
Cork, T12 DC4A, Ireland
St. James Hospital
Dublin, D08 NHY1, Ireland
Galway University
Galway, H91 YR71, Ireland
University Hospital Waterford
Waterford, X91 ER8E, Ireland
Hillel-Yaffe Medical Center
Hadera, 38100, Israel
Wolfson Medical Center
Holon, Israel
Hadassah Medical Center
Jerusalem, 91120, Israel
Sheba Medical Center
Ramat Gan, 52621, Israel
IRCCS Azienda Ospedaliero Universitaria di Bologna
Bologna, 40138, Italy
ASST Spedali Civili Di Brescia
Brescia, 25123, Italy
IRCCS Istituto Romagnolo Per Lo Studio Del Tumori "Dino Amadori" - IRST S.R.L.
Meldola, 47014, Italy
San Raffaele Hospital
Milan, 20132, Italy
Istituto Nazionale dei Tumori IRCCS - MILANO S. C. Ginecologia Oncologica
Milan, 20133, Italy
Instituto Europeo di Oncologia
Milan, 20141, Italy
Humanitas San Pio X Hospital
Milan, 20159, Italy
Ospedale San Gerardo - Asst Monza
Monza, 20900, Italy
"Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" - NAPOLI Struttura Complessa Oncologia Medica Uro-Ginecologica"
Naples, 20133, Italy
Istituto Oncologico Veneto
Padova, 35128, Italy
Universita di Pisa
Pisa, 56127, Italy
Nuovo Ospedale di Prato
Prato, 59100, Italy
Fondazione Policlinico Universitario Agostino Gemelli - ROMA
Roma, 00168, Italy
Ospedale Ostetrico Ginecologico Sant'Anna
Torino, 10124, Italy
AO Ordine Mauriziano
Torino, 10128, Italy
St. Elisabeth Cancer Institute
Bratislava, 81250, Slovakia
UH Bratislava
Bratislava, 82606, Slovakia
National Cancer Institute
Bratislava, 83310, Slovakia
UH Trenčín
Trenčín, 91101, Slovakia
Soon Chun Hyang University Hospital Cheonan
Cheonan, Chungcheongnam-do, 31151, South Korea
Severance Hospital (Yonsei University Health System)
Seoul, Seongbuk, 50-1, South Korea
Samsung Changwon Hospital
Changwon, 51353, South Korea
National Cancer Center (NCC)
Goyang-si, 323, South Korea
CHA University/Bundang CHA General Hospital
Seongnam-si, 59, South Korea
Seoul National University Hospital
Seoul, 03080, South Korea
Gangnam Severance Hospital
Seoul, 06273, South Korea
Seoul National University Bundang Hospital
Seoul, 101, South Korea
Korea University Anam Hospital
Seoul, 73, South Korea
Samsung Medical Center
Seoul, 81, South Korea
Asan Medical Center
Seoul, 88, South Korea
Hospital Universitario Donostia
Donostia / San Sebastian, Gipuzkoa, 20014, Spain
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Zaragoza, 50009, Spain
ICO Badalona
Badalona, 08916, Spain
Hospital Universitari Vall d' Hebrón
Barcelona, 08035, Spain
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
Institut Catala d'Oncologia Hospitalet
Barcelona, 08908, Spain
Hospital Universitario Reina Sofía
Córdoba, 14004, Spain
Institut Catala d'Oncologia de Girona
Girona, 17007, Spain
Hospital Universitario Virgen de las Nieves
Granada, 18014, Spain
MD Anderson Cancer Center Madrid
Madrid, 28033, Spain
Hospital Universitario Ramón y Cajal
Madrid, 28034, Spain
Hospital Universitario Clinico San Carlos
Madrid, 28040, Spain
H 12 de Octubre
Madrid, 28041, Spain
Hospital Universitario La Paz
Madrid, 28046, Spain
Hospital Universitatrio Virgen de la Victoria
Málaga, 29010, Spain
Virgen de la Arrixaca University Clinical Hospital
Murcia, 30120, Spain
Hospital Universitario Virgen del Rocío
Seville, 41013, Spain
Instituto Valenciano de Oncología
Valencia, 46009, Spain
Hospital Clínico Universitario de Valencia
Valencia, 46010, Spain
Hospital LaFe Uacenlia
Valencia, 46026, Spain
Hospital Miguel Servet
Zaragoza, 50009, Spain
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, 833401, Taiwan
TaiChung Veterans General Hospital
Taichung, 407219, Taiwan
Chi Mei Medical Center
Tainan, 71004, Taiwan
Mackay Memorial Hospital
Taipei, 104217, Taiwan
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
Taipei Medical University- Shuang Ho Hospital, Ministry of Health and Welfare
Taipei, 23561, Taiwan
Chang Gung Memorial Hospital
Taoyuan, 333, Taiwan
Ankara Baskent Hospital
Çankaya, Ankara, 34093, Turkey (Türkiye)
Çukurova University
Adana, 01330, Turkey (Türkiye)
Adana Baskent Hospital
Adana, 34920, Turkey (Türkiye)
Hacettepe University Oncology Hospital
Ankara, 06230, Turkey (Türkiye)
Memorial Ankara Hospital
Ankara, 06520, Turkey (Türkiye)
Cerrahpasa University
Istanbul, 34098, Turkey (Türkiye)
Acibadem Atakent Hospital
Istanbul, 34303, Turkey (Türkiye)
Related Publications (3)
Secord AA, Powell MA, McAlpine J. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025 Nov 1;146(5):660-671. doi: 10.1097/AOG.0000000000006080. Epub 2025 Sep 18.
PMID: 40966692DERIVEDMakker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Reginacova K, Richardson DL, Perri T, Oza AM, Miller DS, Alia EMG, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednarikova M, Chon HS, Martinez-Garcia J, Pisano C, Berek JS, Romero I, Scambia G, Farinas-Madrid L, Buscema J, Schochter F, Li K, Kalyanapu P, Walker CJ, Vergote I. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol. 2024 Jun;185:202-211. doi: 10.1016/j.ygyno.2024.05.016. Epub 2024 Jun 3.
PMID: 38834399DERIVEDVergote I, Perez Fidalgo A, Valabrega G, Monk BJ, Herzog T, Cibula D, Colombo N, Pothuri B, Sehouli J, Korach J, Barlin J, Papadimitriou CA, van Gorp T, Richardson D, McCarthy M, Antill Y, Mirza MR, Li K, Kalyanapu P, Slomovitz B, Coleman RL. ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 5;34(8):1283-1289. doi: 10.1136/ijgc-2024-005412.
PMID: 38627035DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Masking Details
- Double blind placebo-controlled study
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 2022
First Posted
November 10, 2022
Study Start
April 18, 2023
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
January 1, 2028
Last Updated
April 23, 2026
Record last verified: 2026-04